Results 331 to 340 of about 857,003 (376)
Some of the next articles are maybe not open access.
Clinical Pharmacology of Lacidipine
Journal of Cardiovascular Pharmacology, 1991The safety and tolerability of lacidipine was assessed in a volunteer population, and its pharmacodynamic and pharmacokinetic profiles evaluated. In normotensive subjects, single oral doses of 3-5 mg of lacidipine produced a dose-related fall in peripheral vascular resistance.
S. T. Hall +4 more
openaire +2 more sources
Rapacuronium: clinical pharmacology
European Journal of Anaesthesiology, 2001The need for a rapid-acting non-depolarizing neuromuscular blocking agent with a short duration of action resulted in the synthesis of rapacuronium. The onset of maximum block with rapacuronium occurs in 60-90 s with doses of 1.5-2.5 mg kg-1 with a duration of clinical relaxation of 15-30 min.
K. C. McCourt, Rajinder K. Mirakhur
openaire +2 more sources
Clinical pharmacology and malaria
Annals of Tropical Medicine And Parasitology, 1997The role of clinical pharmacology in improving the prevention and treatment of malaria is reviewed. A series of general and specific issues is discussed, concentrating on risk-benefit and cost-effectiveness. The techniques of clinical pharmacokinetics play an important role in the optimal use of drugs and this is illustrated by studies on quinine and ...
Alasdair Breckenridge, P. A. Winstanley
openaire +3 more sources
Clinical pharmacology of etoricoxib
Expert Opinion on Drug Metabolism & Toxicology, 2005Etoricoxib is a highly selective COX-2 inhibitor (coxib) approved in Europe for the treatment of osteoarthritis (OA), rheumatoid arthritis and acute gouty arthritis. Etoricoxib is an effective analgesic drug that has shown some improved efficacy versus traditional NSAIDs and it is the only coxib approved for the treatment of acute gouty arthritis ...
CAPONE ML +2 more
openaire +3 more sources
Clinical Pharmacology Of Caffeine
Annual Review of Medicine, 1990Caffeine is the most widely consumed stimulant drug in the world. This chapter reviews the human pharmacology of caffeine; the evidence for its role in causing human disease, including addiction; and its potential usefulness as a therapeutic agent.
openaire +3 more sources
CLINICAL PHARMACOLOGY OF BENZODIAZEPINES
Annual Review of Medicine, 1987The benzodiazepines are the most widely used anxiolytic drugs. Their pharmacokinetic properties differ widely. Side effects are usually mild but dependence can supervene after long-term administration, even if normal therapeutic doses are not exceeded. Careful monitoring of use is essential.
openaire +2 more sources
The chemistry, pharmacology and clinical pharmacology of diflunisal
Current Medical Research and Opinion, 1978Studies are reviewed on diflunisal, a new analgesic agent with an improved therapeutic index, compared with acetylsalicylic acid, in animals and humans. Pharmacokinetic data indicate that a twice-daily dosage regimen of diflunisal is adequate for therapeutic purposes.
V. J. Cirillo +2 more
openaire +3 more sources
Clinical Pharmacology of Nicotine
Annual Review of Medicine, 1986Nicotine is the primary reason why people consume tobacco products and it may contribute to causation of tobacco-related diseases. This chapter reviews the human pharmacology of nicotine, the evidence for a role of nicotine in human disease, and the use of nicotine (gum) as a therapeutic agent in smoking cessation therapy.
openaire +3 more sources
The clinical pharmacology of vasoconstrictors
Clinical Pharmacology & Therapeutics, 1966Vasoconstrictors are mainly used in acute hypotensive states, and they often succeed in bringing about at least a temporary increase in arterial pressure. Pressure is easy to measure, whereas tissue perfusion is not; but it is the latter that is the important variable, and a rise in pressure does not necessarily imply an improved circulation.
A. C. Dornhorst, R. L. Hodge
openaire +3 more sources
Clinical pharmacology – the basics
Surgery (Oxford), 2009Abstract Clinical pharmacology is the study of pharmacodynamics and pharmacokinetics in humans. The relationship between dose, concentration and pharmacodynamic response may be explored using biomarkers for both desired and undesired effects of drugs.
openaire +2 more sources